Knight Therapeutics (TSE:GUD) Stock Price Up 9.2% – Still a Buy?

Shares of Knight Therapeutics Inc. (TSE:GUD) were up 9.2% during trading on Tuesday . The stock traded as high as C$6.04 and last traded at C$5.95. Approximately 215,326 shares were traded during trading, an increase of 313% from the average daily volume of 52,166 shares. The stock had previously closed at C$5.45.

Wall Street Analysts Forecast Growth

Separately, Raymond James raised shares of Knight Therapeutics to a “moderate buy” rating in a research report on Friday, November 15th.

Knight Therapeutics Stock Performance

The company has a debt-to-equity ratio of 7.52, a current ratio of 3.36 and a quick ratio of 1.79. The firm has a market cap of C$626.12 million, a price-to-earnings ratio of -20.67, a P/E/G ratio of -1,013.50 and a beta of 0.50. The firm has a fifty day simple moving average of C$5.55 and a two-hundred day simple moving average of C$5.55.

Insider Activity

In other Knight Therapeutics news, insider Sime Armoyan acquired 17,600 shares of the firm’s stock in a transaction on Tuesday, March 4th. The stock was acquired at an average cost of C$5.48 per share, for a total transaction of C$96,488.48. Corporate insiders own 45.62% of the company’s stock.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.